Human Adenovirus Serotype 5 Is Sensitive to IgM-Independent Neutralization In Vitro and In Vivo.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
05 07 2019
Historique:
received: 25 04 2019
revised: 23 06 2019
accepted: 03 07 2019
entrez: 10 7 2019
pubmed: 10 7 2019
medline: 1 8 2020
Statut: epublish

Résumé

Human adenovirus 5 (HAdV-5) is used as a vector in gene therapy clinical trials, hence its interactions with the host immune system have been widely studied. Previous studies have demonstrated that HAdV-5 binds specifically to murine coagulation factor X (mFX), inhibiting IgM and complement-mediated neutralization. Here, we examined the physical binding of immune components to HAdV-5 by nanoparticle tracking analysis, neutralization assays, mass spectrometry analysis and in vivo experiments. We observed that purified mouse Immunoglobulin M (IgM) antibodies bound to HAdV-5 only in the presence of complement components. Active serum components were demonstrated to bind to HAdV-5 in the presence or absence of mFX, indicating that immune molecules and mFX might bind to different sites. Since binding of mFX to HAdV-5 blocks the neutralization cascade, these findings suggested that not all complement-binding sites may be involved in virion neutralization. Furthermore, the data obtained from serum neutralization experiments suggested that immune molecules other than IgM and IgG may trigger activation of the complement cascade in vitro. In vivo experiments were conducted in immunocompetent C57BL/6 or immuno-deficient

Identifiants

pubmed: 31284434
pii: v11070616
doi: 10.3390/v11070616
pmc: PMC6669743
pii:
doi:

Substances chimiques

Antibodies, Viral 0
DNA-Binding Proteins 0
Immunoglobulin M 0
Rag2 protein, mouse 0
Factor X 9001-29-0
Complement System Proteins 9007-36-7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : British Heart Foundation
ID : CH/11/2/28733
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M011542/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/L027933/1
Pays : United Kingdom

Références

Hum Gene Ther. 1999 Apr 10;10(6):965-76
pubmed: 10223730
Hum Gene Ther. 2002 Jan 1;13(1):113-24
pubmed: 11779415
Hum Gene Ther. 2002 Jan 1;13(1):143-54
pubmed: 11779418
J Virol. 2005 Jun;79(12):7478-91
pubmed: 15919903
Cancer Gene Ther. 2006 Feb;13(2):169-81
pubmed: 16082381
J Clin Microbiol. 2005 Sep;43(9):4426-33
pubmed: 16145087
Blood. 2006 Oct 15;108(8):2554-61
pubmed: 16788098
Blood. 2009 Jul 30;114(5):965-71
pubmed: 19429866
Adv Immunol. 2009;104:115-49
pubmed: 20457117
Blood. 2010 Oct 14;116(15):2656-64
pubmed: 20610817
PLoS Pathog. 2010 Oct 07;6(10):e1001142
pubmed: 20949078
Methods Mol Med. 1999;30:271-83
pubmed: 21341032
Eur J Immunol. 1990 Dec;20(12):2555-61
pubmed: 2148521
Nat Med. 2013 Apr;19(4):452-7
pubmed: 23524342
Mol Cell Proteomics. 2014 Sep;13(9):2513-26
pubmed: 24942700
Expert Opin Drug Deliv. 2014 Nov;11(11):1795-813
pubmed: 25036189
PLoS Pathog. 2015 Feb 06;11(2):e1004673
pubmed: 25658827
Hum Gene Ther. 2015 May;26(5):312-9
pubmed: 25760682
Gene Ther. 2016 Jul;23(7):592-6
pubmed: 27014840
Oncotarget. 2017 Feb 28;8(9):15553-15562
pubmed: 28152519
J Virol. 2017 May 26;91(12):
pubmed: 28381574
PLoS One. 2018 Feb 5;13(2):e0192353
pubmed: 29401488
Cell Host Microbe. 2019 Apr 10;25(4):617-629.e7
pubmed: 30926239
J Immunol. 1998 May 15;160(10):4776-87
pubmed: 9590224
Biochemistry. 1998 Dec 15;37(50):17361-70
pubmed: 9860851

Auteurs

Andor Doszpoly (A)

Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, UK.

Fernando de la Cuesta (F)

Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, UK.

Estrella Lopez-Gordo (E)

Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow G12 8TA, UK.

Cécile Bénézech (C)

Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, UK.

Stuart A Nicklin (SA)

Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow G12 8TA, UK.

Andrew H Baker (AH)

Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, UK. Andy.Baker@ed.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH